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A B S T R A C T
This work evaluated the antitumor eﬀects of albendazole (ABZ) and its relationship with modulation of
oxidative stress and induction of DNA damage. The present results showed that ABZ causes oxidative cleavage
on calf-thymus DNA suggesting that this compound can break DNA. ABZ treatment decreased MCF-7 cell
viability (EC50=44.9 for 24 h) and inhibited MCF-7 colony formation (~67.5% at 5 μM). Intracellular ROS levels
increased with ABZ treatment (~123%). The antioxidant NAC is able to revert the cytotoxic eﬀects, ROS
generation and loss of mitochondrial membrane potential of MCF-7 cells treated with ABZ. Ehrlich carcinoma
growth was inhibited (~32%) and survival time was elongated (~50%) in animals treated with ABZ. Oxidative
biomarkers (TBARS and protein carbonyl levels) and activity of antioxidant enzymes (CAT, SOD and GR)
increased, and reduced glutathione (GSH) was depleted in animals treated with ABZ, indicating an oxidative
stress condition, leading to a DNA damage causing phosphorylation of histone H2A variant, H2AX, and
triggering apoptosis signaling, which was conﬁrmed by increasing Bax/Bcl-xL rate, p53 and Bax expression. We
propose that ABZ induces oxidative stress promoting DNA fragmentation and triggering apoptosis and inducing
cell death, making this drug a promising leader molecule for development of new antitumor drugs.
1. Introduction
Cancer is a major public health problem in many parts of the world.
In Brazil, about 57,000 of new cases of breast cancer were expected to
be diagnosed in 2015 [1]. Standard cancer treatments are surgery,
radiation, immunotherapy and/or chemotherapy. To the moment
cancer management by chemotherapy is one of the most eﬀective
and potent strategies to treat malignant tumors. However, the multi-
drug resistance, which is the mechanism that many cancer cells develop
drug resistance to chemotherapy, has been a signiﬁcant impediment to
successful treatment [2]. On this context, in which increased cancer
diagnosis and lack of an optimal treatment is observed, new therapeu-
tic alternatives are required. On the other hand, drug repositioning is
an important pharmaceutical strategy for drug development because it
is faster and reduces drug risks once the safety and pharmacokinetic
proﬁles of drugs are already well- known. Repositioning can oﬀer a
better risk versus-reward trade-oﬀ compared to other strategies for
drug development. Furthermore, this strategy is economically attrac-
tive when compared to the cost of drug development based on de novo
drug discovery and development [3].
Albendazole (methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)
carbamate; ABZ) is a benzimidazole derivative that was introduced in
1982 as an antihelmintic [4]. The mechanism of action of ABZ is
related to microtubule inhibition and blocking glucose uptake that
causes depletion of glycogen stores and lowering formation of ATP in
the larval and adult stages of susceptible parasites. Altogether, it leads
to immobilization and death of the parasite [5,6]. There are some few
evidences in the literature supporting ABZ repositioning for cancer
therapy. ABZ possesses anti- proliferative eﬀects against several tumor
cell lines [7–10]. Additional reasons to assess ABZ repositioning can be
deduced from the fact that targeting the altered redox status of cancer
cells is an interesting approach for new cancer therapy.
Cancer cells are under high oxidative stress because they possess
altered antioxidant defenses and some researchers claim that reactive
oxygen species (ROS) induced by anticancer drugs produce a shift in
cellular antioxidant machinery as well as in the mitochondrial mem-
brane potential, which are related to induction of programmed cell
death [11]. It is important to stress out that ABZ showed increased
ROS production, thereby promoting oxidative stress [12]. And this
could be used as approach in cancer treatment considering cancer cells
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evading the apoptotic signaling [13]. In addition, due to the role of ROS
as cellular switches for signaling cascades this property could be related
with prooncogenic promotion or antitumorigenic signaling pathways,
making the use of redox-modulating as an interesting strategy for
anticancer therapy [14].
The aim of this work was to evaluate the antitumor eﬀects of ABZ
and relationship with induction of oxidative stress and DNA damage
accessed by oxidative cleavage of CT-DNA, intracellular ROS content in
MCF-7 cells and the related oxidative stress modulation, as well as the
cycle cell arrest in Ehrlich ascites in mice treated with this drug, trying
to characterize ABZ as a molecule prototype for possible drug
repositioning in cancer therapy.
2. Material and methods
2.1. Chemicals and antibodies
Dulbecco's modiﬁed Eagle medium (DMEM), fetal bovine serum
(FBS) and antibiotics were purchased from Gibco (USA). Albendazole
(PubChem CID: 2082), methotrexate, calf thymus DNA (CT-DNA),
agarose, DMSO, 2′,7′-dichloroﬂuorescein diacetate (DCFH-DA), N-
acetyl-L-cysteine (NAC), 5,5′-dithio-bis (2-nitrobenzoic acid) (DTNB),
bovine serum albumin (BSA), ethidium bromide (EtdBr), protease
inhibitor cocktail, hydrogen peroxide, trichloroacetic acid, thiobarbi-
turic acid, glutathione oxidized form (GSSG), NADPH and epinephrine
purchased from Sigma Aldrich (Brazil). The phosphatase inhibitor
cocktail was from Calbiochem (Merck Biosciences). Antibodies against
γH2AX, p53, Bax and Bcl-xL were obtained from Santa Cruz
Biotechnology, Inc. (USA). Mouse antibody against β-actin was from
Millipore (USA). The secondary antibodies and the kit for chemilumi-
nescence detection of HRP-coupled antibodies were from Millipore
(USA). PI/RNAse solution kit from Immunostep (Salamanca, Spain).
2.2. Oxidative cleavage of CT-DNA
CT-DNA oxidative damage was evaluated using CT-DNA (0.5 mM)
in 50 mM phosphate buﬀer (pH 7.2) incubated with 10 μM albendazole
at 37 °C for 24 h. The samples were treated with 2-thiobarbituric acid
1% in 50 mM NaOH and glacial acetic acid, and incubated at 100 °C for
30 min. After cooling, absorbance was measured at 532 nm. The
control had all components except albendazole. Fe(EDTA)-2: H2O2
was used for the positive control (100 μM/10 mM) [15].
2.3. Cytotoxicity, anti-proliferative assay, intracellular levels of ROS
and mitochondrial membrane potential (ΔΨm) determination
Human breast cancer cell line MCF-7 was purchased from the Rio
de Janeiro cell bank, Brazil. Cells were cultured in DMEM high glucose
with FBS 10%, penicillin (100 U/mL) and streptomycin (100 μg/mL).
MTT assay was used to study the eﬀect of ABZ on cell viability [16].
Cells (104 cells/well) were placed on 96-well plates and after con-
ﬂuence they were exposed to ABZ (0–100 μM) for 24 h. Cells were
washed and after 2 h of incubation with MTT (0.5 mg/mL), formazan
crystals were solubilized in DMSO. The colored solutions were read at
550 nm. The results were presented as values of concentration EC50.
Proliferation was evaluated in vitro through the colony forming unit
assay. MCF-7 cells at density of single cells (500 cells) were allowed to
set in six-well plates for 24 h. After, the medium was replaced by other
containing of ABZ and MTX at non- cytotoxic concentrations (5 and
10 μM) and incubated for a further 24 h. In control wells, the cells were
incubated in medium containing only DMSO 0.1%. After treatment, the
cells were washed with warm PBS and fresh medium was provided. The
cells were incubated for 16 days when the proliferation was counted in
terms of colony forming units (CFUs) [17].
Intracellular ROS content were evaluated as reported by [18]. MCF-
7 cells (15,000) were loaded with DCFH-DA (10 μM) in HBSS at 37 °C
and incubated for 30 min. Excess DCFH-DA was removed by washing
with fresh HBSS. After, the cells were incubated for 1 h with ABZ (5–
25 μM) and methotrexate (MTX; at same concentrations), washed
twice with HBSS, and then 100 μl of HBSS/well was added. The
intensity of ﬂuorescence was measured at 485 nm for excitation and
530 nm for emission using a Multiscan microplate reader.
Mitochondrial membrane potential was performed using a ﬂuor-
escent probe TMRE. MCF-7 cells (104/well) were plated in ﬂuorescence
96-well plate, after conﬂuence the cells were treated with diﬀerent
concentrations of ABZ (1, 10 and 100 µM), NAC (5 mM) or ABZ
associated with NAC. After 6 h of treatment the cells were washed once
with HBSS and incubated with TMRE (1 µM) during 20 min at 37 °C.
After the cells were washed once with HBSS, followed by ﬂuorescence
intensity measurement, using excitation peak of 549 nm and emission
of 575 nm.
2.4. Ehrlich carcinoma growth inhibition in mice
The antitumor eﬀects of ABZ were evaluated against the Ehrlich
ascitic carcinoma inoculated into the abdomen of isogenic Balb-c mice
(20 ± 2 g). Animal procedures were conducted in accordance with legal
requirements and the approval of the local ethics committee (CEUA/
UFSC PP00784) and legal requirements (NIH publication #80-23,
revised in 1978). Animals were housed under controlled conditions and
had free access to laboratory food and water.
Tumor induction was carried out by inoculating 5×106 cells of
Ehrlich carcinoma. Twenty-four hours later mice were divided into 3
groups (n=12): The control was treated with saline (50 μl). The test-
group was treated with ABZ 20 mg/kg in the same volume of vehicle
(50 μl). MTX (2.5 mg/kg) was used for the positive control [19]. The
dose of ABZ was chosen previously considering the maximum satura-
tion point of this drug. The treatment started 24 h after tumor
inoculation and the abdominal circumference of all animals was
measured (time zero). It was repeated every 24 h during nine days.
On the tenth day, the abdominal circumference of all animals was
measured. Then, half of each group was euthanized for the evaluation
of the ascitic ﬂuid. Tumor growth was determined using the following
equation [20]: Inhibition of tumor growth (%)=100- [(variation in
waist circumference of the treated group×100)/variation in waist
circumference of the control group]. Mice (n=6) from each group were
kept alive to determine survival time [21,22].
Fig. 1. Evaluation of CT-DNA cleavage in presence of albendazole (ABZ). The analysis
was assessed by absorbance of thiobarbituric reactive species (TBARS) in CT-DNA
(500 μM) treated with ABZ (10 μM). Negative control (NC): phosphate buﬀer. Positive
control (PC): [Fe(EDTA)]2-/H2O2. Data represent the mean of three independent
experiments. Signiﬁcant at ***p < 0.001 compared to the control group.
L.S.E.P.W. Castro et al. Redox Biology 10 (2016) 90–99
91
2.5. Antioxidant defense and oxidative damage biomarkers in Ehrlich
carcinoma
The ascitic ﬂuid of treated Ehrlich ascites-bearing mice was
collected and some markers of oxidative stress were analyzed. Lipid
peroxidation was assessed by the measurement of substances that react
with TBA using the thiobarbituric acid method, as described by [23].
Oxidative damage to proteins was quantiﬁed as carbonyl proteins as
described by [24]. The content of reduced glutathione (GSH) was
determined as described by [25]. Catalase (CAT) activity was deter-
mined kinetically through the method described by [26] based on the
decomposition of H2O2 and the decrease in absorbance at 240 nm.
Superoxide dismutase (SOD) activity was measured by monitoring the
oxidation of adrenaline to adrenochrome as described by [27].
Glutathione reductase (GR) activity was determined by measuring
the rate of NADPH oxidation at 340 nm [28]. The reaction was
monitored spectrophotometrically at 340 nm [29]. In general, the
results were normalized by the content of proteins determined by the
Lowry method [30].
2.6. DNA damage in Ehrlich ascitic carcinoma cells
The comet assay was performed to evaluate DNA fragmentation in
tumor cells from treated mice [31]. Cells were resuspended in low-
melting point agarose 0.75% and deposited on the surface of a slide
covered by a thin layer of agarose 1.5%. This was allowed to set for
10 min at room temperature. The slides were submerged (2 h) in a lysis
solution (2.5 M NaCl; 10 mM Tris; 100 mM EDTA; 1% Triton X-100%
and 10% DMSO; pH 10.0) and after submitted to horizontal electro-
phoresis at 300 mA, 8 °C for 20 min in a tank with buﬀer (300 mM
NaOH; 1 mM EDTA; pH 13). A neutralizing solution (0.4 M Tris HCl;
pH 7.5) was added (3 times) followed by washing in water and dryness.
After 10 min in a ﬁxing solution (15% TCA; 5% ZnSO4; 5% glycerol) the
slides were washed and dried again. Slides were stained with ethidium
bromide (0.5 mg/mL) and analyzed under a ﬂuorescence microscope.
Each nucleus received an arbitrary value ranging from 0 (undamaged)
to 4 (maximal damage) [32].
2.7. Cell death assessmentand cell cycle arrest in Ehrlich carcinoma
Tumor cells in the ascitic ﬂuid (25 μl) were stained using a solution
(5 μl) of acridine orange (200 μM) and ethidium bromide (250 μM).
Samples were mixed with the staining just prior to microscopy. Cells
(300) were visualized and categorized on microscope slides. Live cells
appear uniformly green. Early apoptotic cells stain green and contain
bright green dots in the nuclei. Late apoptotic cells also incorporate
ethidium bromide and therefore stain orange, but, in contrast to
necrotic cells, the late apoptotic cells show condensed and often
fragmented nuclei [33].
Cell cycle arrest was evaluated using a PI/RNAse solution kit from
Immunostep (Salamanca, Spain) using the procedure suggested by the
manufacturer. Ehrlich tumor cells (5×105) were carefully washed with
PBS, pelleted and ﬁxed by rapid submersion in ice-cold ethanol (70%)
with vigorous vortexing. After overnight ﬁxation at −20 °C the cells
were washed with PBS, pelleted, resuspended and incubated (15 min,
under room temperature) with PI/RNAse solution. Finally, cells were
evaluated by the FACSCanto II (BD Biosciences) cytometer. Data were
processed using the Flowing Software 2.5.1.
Fig. 2. Evaluation of MCF-7 cell lines treated with albendazole (ABZ) and methotrexate (MTX). (A) In vitro cytotoxicity of ABZ and MTX in MCF-7 cells. EC50 values obtained by the
MTT reduction assay after 24 h treatment (1–100 μM). (B) Inhibition of cell proliferation assessed by colony formation assay after treatment with ABZ and MTX at 5 and 10 μM. (C)
Content of Intracellular ROS in MCF-7 cells after treatment with ABZ and MTX at 5 and 25 μM, for 1 h. Data represent the mean of three independent experiments. Values are expressed
as mean ± S.E.M, n=3. * and *** denote statistical diﬀerence compared to non-treated cells of the control when p < 0.1 and p < 0.001, respectively. ## and ### denote statistical
diﬀerence between ABZ and MTX treatment when p < 0.01 and p < 0.001, respectively.
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2.8. Western blots analysis
After treatments, Ehrlich tumor cells were carefully washed with
PBS and lysed in RIPA buﬀer (50 mM Tris-Cl; pH 7.4; 150 mM NaCl;
1% NP40; 0,25% Na-deoxycholate and 1 mM phenylmethylsulfonyl
ﬂuoride) supplemented with 1% protease inhibitor and 3% phospha-
tase inhibitor cocktails. After denaturation in Laemmli buﬀer (60 mM
Tris-Cl; pH 6.8; 2% SDS; 10% glycerol; 5% β- mercaptoethanol; 0.01%
bromophenol blue), equal amounts of protein (25 μg) from whole
cellular homogenates were subjected to SDS-PAGE electrophoresis
Fig. 3. Evaluation of MCF-7 cell line treated with albendazole (ABZ) and N-acetyl-L-cysteine (NAC). (A) In vitro cytotoxicity of ABZ (1–100 μM) and NAC (5 mM) in MCF-7 cells. MTT
reduction assay after 24 h treatment. (B) Content of Intracellular ROS in MCF-7 cells after treatment with ABZ (5, 10 and 15 μM) and NAC (5 mM), for 4 h. (C) Mitochondrial
membrane potential (ΔΨm) determination in MCF-7 cells after treatment with ABZ (1–100 μM) and NAC (5 mM), for 6 h. Data represent the mean of three independent experiments.
Values are expressed as mean ± S.E.M, n=3. * and ** denote statistical diﬀerence compared to non-treated cells of the control when p < 0.1 and p < 0.01, respectively. ## and ### denote
statistical diﬀerence between ABZ and NAC treatment when p < 0.01 and p < 0.001, respectively.
Fig. 4. Antitumor activity of albendazole (ABZ, 20 mg/kg) and methotrexate (MTX, 2.5 mg/kg, positive control) against Ehrlich Ascites Carcinoma in balb-c mice. (A) ABZ and MTX
growth tumor inhibition analysis. (B) Increased survival time of Ehrlich Ascites Carcinoma-bearing mice treated with ABZ or MTX. Values are expressed as mean ± S.E.M, n=12.***
denote statistical diﬀerence compared to non-treated cells of the control (saline group) when p < 0.001.
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followed by electroblot to nitrocellulose membranes. After blocking and
washing, the membranes were incubated overnight with the primary
antibodies, washed again and further incubated with the secondary
antibodies. Primary antibodies were: polyclonal rabbit anti-p-Histone
H2AX from Santa Cruz Biotechnology (sc-101696), anti- p53 from
Santa Cruz Biotechnology (sc-6243), mouse monoclonal antibody
against Bax (sc- 7480) and Bcl-xL (sc-8392) were from Santa Cruz
Biotechnology Inc. Mouse antibody against β-actin, the secondary
antibodies and the kit for chemiluminescence detection of HRP-
coupled antibodies were from Millipore (USA).
2.9. Statistical analysis
In vitro assays were performed in triplicate and repeated three
times independently. In vivo assays were performed with n=12. Data
were recorded as means ± S.E.M. or percentages. Data were analyzed
by the ANOVA test followed by the Bonferroni test. Comparisons were
done using GraphPad Prism software (version 5.01). Values of p < 0.05
were considered statistically signiﬁcant.
Fig. 5. Markers of oxidative stress and antioxidant defenses in Ascitic ﬂuid from Ehrlich tumor cells from mice treated with Albendazole (ABZ, 20 mg/kg) or methotrexate (MTX,
2.5 mg/kg, positive control). The treatment caused molecular damage on (A) lipids (lipoperoxidation) and (B) proteins (carbonylation) and consuming (C) GSH in tumor cells. The
activity of antioxidant enzymes increased: (D) superoxide dismutase (SOD), (E) catalase (CAT) and (F) glutathione reductase (GR). Values are expressed as mean ± S.E.M, n=12.
Signiﬁcant at *p < 0.05, **p < 0.01 and ***p < 0.001 compared to control group (saline group). ##p < 0.01 and ###p < 0.001 indicated signiﬁcance between the ABZ and MTX groups.
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3. Results and discussion
In cancer cells the interactions between antitumor drugs and DNA
result in cell damage and target cell death [34]. CT-DNA treated with
ABZ underwent oxidative damage (Fig. 1) and this was considered
positive because DNA damage could provide therapeutic opportunities
to treat cancer [35,36]. Several factors can alter the structure of DNA,
such as UV radiation, reactive oxygen and nitrogen species, as well as
extrinsic chemical compounds [37]. Drugs able to oxidize DNA at C4 of
deoxyribose cause DNA breakage thereby generating products of DNA
degradation such as the base propenal, which is a TBA-reactive product
[38,39]. ABZ treatment overgenerates ROS therefore being able to
oxidize DNA at C4 of deoxyribose causing DNA breakage which is
detected by TBARS, showing that ABZ have a direct action on puriﬁed
DNA.
Treatment with ABZ and MTX inhibited cell viability in a concen-
tration dependent manner (Fig. 2A). The EC50 value was calculated
considering experiments performed after 24 h of incubation and the
EC50 value obtained were 44.9 and 45.7 μM respectively, suggesting a
very high ABZ and MTX cytotoxicity to MCF-7 cells.
In accordance, the anti-proliferative evaluation showed that ABZ
and MTX treatments inhibited the MCF-7 colony formation (Fig. 2B),
however in comparison with MTX the eﬀect of ABZ at same concen-
tration was more pronounced. The colony formation inhibition after
ABZ treatment was approximately 67.5% for 5 μM and at 10 μM no
colony formation was observed. MTX at same concentrations inhibited
approximately 36% and 50%, respectively.
The content of intracellular ROS increased in MCF-7 cells treated
with ABZ (Fig. 2C), at a concentration-dependent manner. These
results suggest that ROS overgeneration could be involved in the
cytotoxicity eﬀects of MCF-7 cells treated with ABZ, because ROS
can activate Bax thereby triggering apoptosis and reducing the cell
viability [40,41].
In attempt to verify if the ABZ ROS generation is aﬀected in
presence of antioxidant compounds we analyzed the ABZ eﬀects in
presence of N-acetyl-L-cysteine (NAC). The cytotoxic eﬀects observed
in MCF-7 cells treated with ABZ were reversed in presence of NAC
(Fig. 3A), however NAC is not able to complete abolish ABZ eﬀects
upon MCF-7 cells in the higher concentration. The intracellular ROS
increased due ABZ treatment (Fig. 3B) is completely reversed in
presence of NAC in all treatment. The analysis of mitochondrial
membrane potential (ΔΨm) showed that the presence of ABZ
(100 µM) decreased the ΔΨm (Fig. 3C) but NAC is able to restored
this eﬀect. Loss of ΔΨm renders cells depleted of energy with
subsequent death, showing a direct eﬀect of ABZ ROS generation and
apoptosis triggering.
The in vivo assay to verify the antitumor activity using Ehrlich
ascites carcinoma-bearing mice showed that ABZ (20 mg/kg) caused
32% of tumor growth inhibition (Fig. 4A), while MTX (2.5 mg/kg)
caused nearly 55%. In addition, MTX and ABZ treatments elongated
the survival time of the animals (Fig. 4B). The diﬀerence between MTX
and ABZ eﬀects may be due to the related ABZ low bioavailability, for
this reason pharmacokinetic and structure activity studies are needed
aiming to improve the solubility of this drug. In attempt to verify if the
mechanism beyond ABZ antitumor activity involves ROS biosignaling,
oxidative stress markers were analyzed using the ascitic ﬂuid. In this
regard, increased oxidative markers were detected, MDA content was
12.9-fold higher compared to controls for ABZ treatment and 7.2-fold
higher compared to controls for MTX (Fig. 5A). Similarly, carbonyl
protein (Fig. 5B) also increased for ABZ (6.4-fold) and MTX (2.0-fold)
compared to controls. However, ABZ showed a more potent ROS
generation ability compared to MTX. Accordingly, biomarkers of
oxidative stress are directly connected with changes of ROS concentra-
tions [42,43]. When antioxidant defenses are impaired or overcome,
oxidative stress enhances lipid peroxidation and protein carbonyl
formation [44]. In some cases, the formation of carbonyl derivatives
could be nonreversible, causing conformational changes and decreas-
ing catalytic activity in antioxidant enzymes [45]. Also, it is well known
that ROS or oxidants are involved in the induction of apoptosis as well
as in necrosis [46].
Fig. 6. Albendazole (ABZ, 20 mg/kg) and Methotrexate (MTX, 2.5 mg/kg, positive control) eﬀects on DNA of Ascitic ﬂuid from Ehrlich ascitic carcinoma cells. (A) DNA damage
indexdetermined by the comet assay and (B) γH2AX was assessed by immunoblotting. Values are expressed as mean ± S.E.M. Signiﬁcant at ***p < 0.001 compared to control group
(saline group).###p < 0.001 indicated signiﬁcance between the ABZ and MTX groups.
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Whereas the levels of the tri-peptide GSH were drastically de-
creased, all activity of antioxidant enzymatic such as SOD, CAT and GR
were increased after treatment with both drugs. Taken together, these
ﬁndings are indicative of an oxidative stress increased caused by ABZ
and MTX treatments, stressing out that ABZ presented a greater eﬀect
compared to MTX.
A drastic depletion of GSH content (Fig. 5C) for ABZ (96.77%) and
MTX (81.87%) was observed compared to controls, despite the
increased of GR activity (2.5 and 1.3-fold compared to controls for
ABZ and MTX, respectively), suggesting that ABZ is a potent ROS
generator (Fig. 5F). The GSH redox system is important for attenuating
oxidative stress and in this process, GSH as a generalist radical
scavenger, is converted to oxidized glutathione (GSSG), while GR
continuously converts GSSG back to GSH [47]. Accordingly, the
increased GR activity observed in both treatments could be justiﬁed
by ROS overproduction, which is known to increase GR activity [48]. In
this context, our results showed that both ABZ and MTX increased ROS
generation concomitantly to GSH depletion and GR upregulation.
In cancer cell GSH metabolism is usually upregulated, suggesting
that cancer cells depend on GSH metabolism [49]. Therefore, cancer
cells appear to rely heavily on GSH reducing equivalents to maintain
redox homeostasis to face oxidative challenge, while GSH manipulation
by limiting its synthesis and/or inhibiting its redox recycling have been
shown to be an eﬀective way of sensitizing this kind of cell clonogens to
cell death. The role of GSH redox in cell apoptosis in a variety of cell
types [50] indicates the importance in use such strategy in tumor cells
growth inhibition.
According to [51] SOD and CAT inhibition is result of tumor
growth, while the increased activity of both enzymes is important for
tumor inhibition. Accordingly, ABZ and MTX revealed to be potent
tumor inhibitors, probably as a consequence of their ability to
upregulate SOD and CAT activity (Fig. 5 D and E). ABZ increased
1.64-fold SOD activity and 2.22-fold CAT activity, whereas MTX
increased 1.13 and 1.73, respectively. In addition, according to [12],
in a comparative study of oxidative stress induced by ABZ, increased
SOD activity would render higher H2O2 concentrations inside the cells,
which is in agreement with the high CAT activity found under ABZ
treatment (Fig. 5E). Moreover, relatively slight increases in intracel-
lular H2O2 can elicit apoptosis and, in accordance to ours results, ABZ
promoted increased ROS generation as well as SOD and CAT activity,
leading to apoptotic cell death. MXT induced SOD and CAT activity
whereas, ABZ revealing a greater enzymatic increase.
In the context of modulation of oxidative stress by ABZ, DNA
damage and increased apoptotic cell death in Ehrlich cells, were both
veriﬁed after ABZ treatment. DNA fragmentation was measured
(Fig. 6A) and the result showed a strong DNA damage in Erhlich cells
treated with ABZ (damage index of 99.5), again more pronounced
compared to MTX (73.0). These damages could be associated with
increased ROS generation promoted by ABZ, aﬀecting DNA cells. This
result was conﬁrmed by the immunoblotting assay (Fig. 6B), showing
that ABZ treatment increased the content of γH2AX (5.1-fold when
compared with controls), an eﬀect again more than MTX treatment
(2.5). In agreement, cell death results showed that the DNA fragmenta-
tion damage caused by ABZ-induced ROS generation, was probably
responsible for the increased cell death by apoptosis. A strong ABZ
increase of apoptosis cell (5.4-fold when compared with controls),
Fig. 7. Albendazole (ABZ, 20 mg/kg) and Methotrexate (MTX, 2.5 mg/kg, positive control) induce apoptosis and necrosis. (A) Detection of apoptosis by the acridine orange/ethidium
bromide staining. (B) Pro and anti-apoptotic protein p53, Bax and Bcl-xL were assessed by immunoblotting. Signiﬁcant at ***p < 0.001, and *p < 0.05 compared to control group (saline
group). #p < 0.05 indicated signiﬁcance between the ABZ and MTX groups.
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whereas the viable cell was drastically reduced (Fig. 7A). Besides, MTX
increased apoptosis (5.3-fold compared with controls), raised necrosis
rate (9.2-fold compared with controls), responses that were not
observed after the ABZ treatment. This result was conﬁrmed by the
immunoblotting assay (Fig. 7B), ABZ and MTX treatments when
compared with controls showed an increase of p53 and pro-apoptotic
Bax expression, whereas the anti-apoptotic Bcl-xL expression was
diminished.
According to [52], it is well established that oxidative stress
exposure induces DNA damage in cells. γH2AX is a variant of histone
H2A, which is phosphorylated at ser139 in response to DNA damage
[53]. In this way, ROS can activate p53 [54], which, in accordance to
[49], after p53 activation the expression of various proapoptotic factors
occurs, including Bax. In turn, Bax activation leads to an upstream of
apoptotic pathways converging into a ﬁnal stage of cell self-destruction.
Also, increasing the ratio of mitochondrial Bax/Bcl-xL induces Bax
activation and cytochrome c release from mitochondria in the presence
of a BH3-only protein, tBid, in a cell-free system [55]. In addition, p53
control apoptosis in response to abnormal proliferative signals and
stress including DNA damage [56]. Our results showed an increase of
this correlation rate of Bax/Bcl-xL, thereby conﬁrming that ABZ
induces mitochondrial-associated pathway of apoptosis (Fig. 7B) in a
greater rate compared to MTX. This correlation rate of Bax/Bcl-xL
increase is in accordance with p53 increase, because p53-dependent
apoptosis is involved with mitochondrial cytochrome c release [56].
Finally, the cell cycle analysis (Fig. 8A) demonstrating that Ehrlich
ascitic carcinoma (EAC) cells treated with albendazole and methotrex-
ate showed a diﬀerent cell cycle proﬁle compared with non-treated EAC
cells (control). Both treatments diminished the number of cells G1
phase compared with control. Ours results (Fig. 8A and B) showed that
ABZ besides inhibits G1 phase arrest G2/M phase in EAC carcinomas
as expected, suggesting that ABZ mechanism of action in this cellular
type appears to be related with tubulin polymerization inhibition [57].
In this context, microtubules (heterodimer composed of α tubulin and
β tubulin subunits) are indispensable for the formation and disap-
pearance of the mitotic spindle, in other words, they are responsible for
separation of duplicated chromosomes during cell division, while
disruption of microtubule dynamics by inhibiting polymerization or
preventing depolymerization of tubulin, thereby promoting cell cycle
arrest on G2/M phase [57,58]. MTX analysis showed that G1 phase
was inhibited and S phase was arrested. In this context, the EAC
growth inhibition treated with MTX could be related with the modula-
tion of pathways including inhibition of G0/G1-S phase cell cycle
progression and induction of apoptosis [59], as well as S phase arrest,
which is associated with growth-inhibitory activity. Such eﬀects of
growth inhibition, induction of apoptosis and S-G2-phase cell cycle
arrest have been already described [60] in HL60 promyelocytic
leukemia cells treated with resveratrol. Accordingly, [61] showed that
Bladder Carcinoma Cell Line Growth Inhibition is mediated by S/G2-M
cell cycle arrest and apoptosis using ciproﬂoxacin.
4. Conclusion
The ABZ-modulation oxidative stress revealed an interesting ap-
Fig. 8. Albendazole (ABZ, 20 mg/kg) and Methotrexate (MTX, 2.5 mg/kg, positive control) inﬂuence on the cell cycle regulation. Percentage of EAC cells in sub G1, G1, S and G2/M
phases after treatment with ABZ. Signiﬁcant at **p < 0.01 and ***p < 0.001 compared to control group (saline group).
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proach regarding cancer treatment. ROS generation promoted by ABZ
in vitro seems to be responsible for sensitizing the cell death in human
breast cancer cells, probably due to the strong inhibition in prolifera-
tion and viability of these cells. ABZ treatment in vivo also indicated to
be related with oxidative stress pathway, leading to depletion of
reduced glutathione levels, to augmentation of important oxidative
biomarkers and activity of antioxidant enzymes, as well as promoting
EAC cells to an impaired antioxidant defense system in relation to
normal cells, thereby inducing activation of apoptosis pathway.
Moreover, ABZ is able to break the CT-DNA in vitro, while in EAC
cells the drug seems to be involved in epigenetic modiﬁcation
associated with DNA damage by inducing DNA fragmentation, as well
as increasing the expression of pro-apoptotic proteins. All these eﬀects
are underlined by a signiﬁcant anticancer in vivo action, indicating
ABZ as a molecule prototype in possible drug repositioning for human
breast cancer treatment.
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